Leticia Calahorra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Leticia Calahorra has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Javier Carbone
Clinical Immunology Department, Hospital General Universitario Gregorio Marañon, Madrid, Spain
6 shared publications Joaquin Navarro
Clinical Immunology Department Hospital General Universitario Gregorio Marañon Madrid Spain
6 shared publications- Diego Clemente
Neuroimmune-Repair Group. Hospital Nacional de Parapléjicos-SESCAM. Toledo, Spain
5 shared publications - Elizabeth Sarmiento
Clinical Immunology Department, Hospital General Universitario Gregorio Marañon, Madrid, Spain
5 shared publications - Mari Paz Serrano-Regal
Neuroimmune-Repair Group. Hospital Nacional de Parapléjicos-SESCAM. Toledo, Spain
5 shared publications - María Cristina Ortega
Centro de Biología Molecular Severo Ochoa, CSIC-UAM, Madrid, Spain
5 shared publications
Latest Publications
- Open Access
Monocytic myeloid-derived suppressor cells, but not regulatory T cells, track immunoregulatory dynamics and relapse recovery in early RRMS
Introduction: Incomplete recovery from relapses contributes to long-term disability accumulation in relapsing–remitting multiple sclerosis (RRMS), yet the relationship between immune regulation and relapse recovery remains poorly defined. Objective: To longitudinally characterize regulatory/effector immune cell dynamics in untreated RRMS patients and assess their association with immune balance and relapse recovery. Methods: Monocytic myeloid-derived suppressor cells (M-MDSCs), regulatory T cells (Treg), and effector CD4⁺ T cell subsets were measured in blood from 69 untreated RRMS patients sampled during relapse or remission and re-evaluated after 12 months. Associations with clinical recovery after relapse were examined. Results: During relapse, patients exhibited higher M-MDSC and Treg frequencies than in remission, while effector T cell subsets remained unchanged. Over one year, M-MDSCs increased consistently regardless of baseline clinical status, whereas Treg frequencies remained stable. Effector-to-M-MDSC ratios were markedly elevated during relapse and declined over time, while effector-to-Treg ratios showed minimal variation. M-MDSC levels during relapse were associated with sustained regulatory features at 12-month follow-up. Importantly, higher baseline M-MDSC levels, but not Treg frequencies, were associated with complete relapse recovery at one year. Conclusion: These findings suggest that circulating M-MDSCs, but not Treg, reflect interindividual differences in immune regulation and clinical recovery after relapse in early RRMS.
Open AccessMonocytic myeloid-derived suppressor cells, but not regulatory T cells, track immunoregulatory dynamics and relapse recovery in early RRMS
Introduction: Incomplete recovery from relapses contributes to long-term disability accumulation in relapsing–remitting multiple sclerosis (RRMS), yet the relationship between immune regulation and relapse recovery remains poorly defined. Objective: To longitudinally characterize regulatory/effector immune cell dynamics in untreated RRMS patients and assess their association with immune balance and relapse recovery. Methods: Monocytic myeloid-derived suppressor cells (M-MDSCs), regulatory T cells (Treg), and effector CD4⁺ T cell subsets were measured in blood from 69 untreated RRMS patients sampled during relapse or remission and re-evaluated after 12 months. Associations with clinical recovery after relapse were examined. Results: During relapse, patients exhibited higher M-MDSC and Treg frequencies than in remission, while effector T cell subsets remained unchanged. Over one year, M-MDSCs increased consistently regardless of baseline clinical status, whereas Treg frequencies remained stable. Effector-to-M-MDSC ratios were markedly elevated during relapse and declined over time, while effector-to-Treg ratios showed minimal variation. M-MDSC levels during relapse were associated with sustained regulatory features at 12-month follow-up. Importantly, higher baseline M-MDSC levels, but not Treg frequencies, were associated with complete relapse recovery at one year. Conclusion: These findings suggest that circulating M-MDSCs, but not Treg, reflect interindividual differences in immune regulation and clinical recovery after relapse in early RRMS.
- Open Access
Circulating Myeloid-Derived Suppressor Cell load and disease severity are associated to an enhanced oligodendroglial production in a murine model of multiple sclerosis
Background: Multiple sclerosis (MS) is a chronic, inflammatory and demyelinating disease of the central nervous system (CNS) that is highly heterogeneous in terms of disease severity and tissue damage extent. Improving myelin restoration is essential to prevent neurodegeneration and the associated disability in MS patients. However, remyelinating therapies are failing in clinical trials, in part, due to the absence of classifying biomarkers of different endogenous regenerative capacities amongst enrolled patients. We previously reported that circulating monocytic myeloid-derived suppressor cells (M-MDSCs) at the onset of the murine model of MS experimental autoimmune encephalomyelitis (EAE) are associated with milder disease courses and less degree of demyelination and axonal damage in spinal cord lesions, while at peak are indicative of a better symptom recovery. Moreover, M-MDSCs are able to promote in vitro oligodendrocyte precursor cell (OPC) proliferation and differentiation towards mature oligodendrocytes (OLs) through the release of the soluble factor osteopontin. Results: Here, we show a relationship between disease severity and a gradient of OPCs between the rim and the core in mixed active-inactive lesions of MS patients, along with a positive correlation between M-MDSC density and OPC abundance in the same lesions. We also show that EAE disease severity negatively influences the density of total and newly generated OPCs found associated to the demyelinated lesions of the spinal cord at the peak of the disease. In addition, disease severity also impacts the abundance of newly generated OLs originated either during the effector phase or during the early recovery phase. We also demonstrate the positive association between infiltrated M-MDSCs and the abundance of OPCs in the periplaque of demyelinating lesions at the peak of EAE. Interestingly, circulating M-MDSCs at EAE onset and peak of the disease are directly associated to a higher density of newly generated OLs in the plaque and periplaque, respectively. Conclusion: Disease severity clearly impacts oligodendrocyte generation during a neuroinflammatory insult like EAE. Our results set the basis for further studies on M-MDSCs as a promising new biomarker that identify a CNS prone to the generation of new OLs that may contribute to restore myelin.
Open AccessCirculating Myeloid-Derived Suppressor Cell load and disease severity are associated to an enhanced oligodendroglial production in a murine model of multiple sclerosis
Background: Multiple sclerosis (MS) is a chronic, inflammatory and demyelinating disease of the central nervous system (CNS) that is highly heterogeneous in terms of disease severity and tissue damage extent. Improving myelin restoration is essential to prevent neurodegeneration and the associated disability in MS patients. However, remyelinating therapies are failing in clinical trials, in part, due to the absence of classifying biomarkers of different endogenous regenerative capacities amongst enrolled patients. We previously reported that circulating monocytic myeloid-derived suppressor cells (M-MDSCs) at the onset of the murine model of MS experimental autoimmune encephalomyelitis (EAE) are associated with milder disease courses and less degree of demyelination and axonal damage in spinal cord lesions, while at peak are indicative of a better symptom recovery. Moreover, M-MDSCs are able to promote in vitro oligodendrocyte precursor cell (OPC) proliferation and differentiation towards mature oligodendrocytes (OLs) through the release of the soluble factor osteopontin. Results: Here, we show a relationship between disease severity and a gradient of OPCs between the rim and the core in mixed active-inactive lesions of MS patients, along with a positive correlation between M-MDSC density and OPC abundance in the same lesions. We also show that EAE disease severity negatively influences the density of total and newly generated OPCs found associated to the demyelinated lesions of the spinal cord at the peak of the disease. In addition, disease severity also impacts the abundance of newly generated OLs originated either during the effector phase or during the early recovery phase. We also demonstrate the positive association between infiltrated M-MDSCs and the abundance of OPCs in the periplaque of demyelinating lesions at the peak of EAE. Interestingly, circulating M-MDSCs at EAE onset and peak of the disease are directly associated to a higher density of newly generated OLs in the plaque and periplaque, respectively. Conclusion: Disease severity clearly impacts oligodendrocyte generation during a neuroinflammatory insult like EAE. Our results set the basis for further studies on M-MDSCs as a promising new biomarker that identify a CNS prone to the generation of new OLs that may contribute to restore myelin.
- Open Access
- 5 November 2023
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 15, S272-S273
EVOBRUTINIB TREATMENT REDUCES THE DAMAGE TO THE CNS AND INCREASES THE NUMBER OF CLASSICAL DENDRITIC CELLS IN EXPERIMENTAL MULTIPLE SCLEROSIS
- 5 November 2023
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 15, S272-S273
Open AccessEVOBRUTINIB TREATMENT REDUCES THE DAMAGE TO THE CNS AND INCREASES THE NUMBER OF CLASSICAL DENDRITIC CELLS IN EXPERIMENTAL MULTIPLE SCLEROSIS
- Open Access
- 5 November 2023
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 15, S290-S291
CIRCULATING MYELOID-DERIVED SUPPRESSOR CELLS AS A POTENTIAL BIOINDICATOR OF THE ENDOGENOUS MYELIN REPAIR CAPACITY IN EXPERIMENTAL MULTIPLE SCLEROSIS
- 5 November 2023
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 15, S290-S291
Open AccessCIRCULATING MYELOID-DERIVED SUPPRESSOR CELLS AS A POTENTIAL BIOINDICATOR OF THE ENDOGENOUS MYELIN REPAIR CAPACITY IN EXPERIMENTAL MULTIPLE SCLEROSIS
- Open Access
- 1 February 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (2) , 335
Regulatory Cells in Multiple Sclerosis: From Blood to Brain
Multiple sclerosis (MS) is a chronic, autoimmune, and neurodegenerative disease of the central nervous system (CNS) that affects myelin. The etiology of MS is unclear, although a variety of environmental and genetic factors are thought to increase the risk of developing the disease. Historically, T cells were considered to be the orchestrators of MS pathogenesis, but evidence has since accumulated implicating B lymphocytes and innate immune cells in the inflammation, demyelination, and axonal damage associated with MS disease progression. However, more recently the importance of the protective role of immunoregulatory cells in MS has become increasingly evident, such as that of myeloid-derived suppressor cells (MDSCs), regulatory T (Treg) and B (Breg) cells, or CD56bright natural killer cells. In this review, we will focus on how peripheral regulatory cells implicated in innate and adaptive immune responses are involved in the physiopathology of MS. Moreover, we will discuss how these cells are thought to act and contribute to MS histopathology, also addressing their promising role as promoters of successful remyelination within the CNS. Finally, we will analyze how understanding these protective mechanisms may be crucial in the search for potential therapies for MS.
- 1 February 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (2) , 335
Open AccessRegulatory Cells in Multiple Sclerosis: From Blood to Brain
Multiple sclerosis (MS) is a chronic, autoimmune, and neurodegenerative disease of the central nervous system (CNS) that affects myelin. The etiology of MS is unclear, although a variety of environmental and genetic factors are thought to increase the risk of developing the disease. Historically, T cells were considered to be the orchestrators of MS pathogenesis, but evidence has since accumulated implicating B lymphocytes and innate immune cells in the inflammation, demyelination, and axonal damage associated with MS disease progression. However, more recently the importance of the protective role of immunoregulatory cells in MS has become increasingly evident, such as that of myeloid-derived suppressor cells (MDSCs), regulatory T (Treg) and B (Breg) cells, or CD56bright natural killer cells. In this review, we will focus on how peripheral regulatory cells implicated in innate and adaptive immune responses are involved in the physiopathology of MS. Moreover, we will discuss how these cells are thought to act and contribute to MS histopathology, also addressing their promising role as promoters of successful remyelination within the CNS. Finally, we will analyze how understanding these protective mechanisms may be crucial in the search for potential therapies for MS.
- 16 October 2020
- Published by Wiley in Transplant Infectious Disease
- Vol. 23 (2) , e13494
Secondary antibody deficiency is associated with development of infection in kidney transplantation: Results of a multicenter study
Background: We performed a multicenter study to assess the association between secondary antibody deficiency (immunoglobulin G [IgG] hypogammaglobulinemia combined with low levels of specific antibodies) and development of infection in kidney transplantation.Methods: We prospectively analyzed 250 adult kidney recipients at four centers. The assessment points were before transplantation and 7 and 30 days after transplantation. The immune parameters were as follows: IgG, IgA, and IgM and complement factors C3 and C4 tested by nephelometry; specific IgG antibodies to cytomegalovirus (CMV) and IgG and IgG2 antibodies to pneumococcal polysaccharide (anti‐PPS) determined using enzyme‐linked immunosorbent assay. The clinical follow‐up period lasted 6 months. The clinical outcomes were CMV disease and recurrent bacterial infections requiring antimicrobial therapy. Statistics: Multivariate logistic regression.Results: At day 7, IgG hypogammaglobulinemia (IgG levels < 700 mg/dL) combined with low IgG anti‐CMV antibody titers (defined as levels < 10 000 units) was present in 12% of kidney recipients. IgG hypogammaglobulinemia combined with low IgG anti‐PPS antibody titers (defined as levels < 10 mg/dL) at 1 month after kidney transplantation were recorded in 16% of patients. At day 7 the combination of IgG hypogammaglobulinemia and low anti‐CMV titers was independently associated with the development of CMV disease (odds ratio [OR], 6.95; 95% confidence interval [CI], 1.17‐41.31; P = .033). At day 30 after transplantation, the combination of IgG < 700 mg/dL and IgG anti‐PPS < 10 mg/dL, was independently associated with recurrent bacterial infection (OR, 5.942; 95% CI, 1.943‐18.172; P = .002).Conclusion: In a prospective multicenter study, early immunologic monitoring of secondary antibody deficiency proved useful for the identification of kidney recipients who developed severe infection.
- 16 October 2020
- Published by Wiley in Transplant Infectious Disease
- Vol. 23 (2) , e13494
Secondary antibody deficiency is associated with development of infection in kidney transplantation: Results of a multicenter study
Background: We performed a multicenter study to assess the association between secondary antibody deficiency (immunoglobulin G [IgG] hypogammaglobulinemia combined with low levels of specific antibodies) and development of infection in kidney transplantation.Methods: We prospectively analyzed 250 adult kidney recipients at four centers. The assessment points were before transplantation and 7 and 30 days after transplantation. The immune parameters were as follows: IgG, IgA, and IgM and complement factors C3 and C4 tested by nephelometry; specific IgG antibodies to cytomegalovirus (CMV) and IgG and IgG2 antibodies to pneumococcal polysaccharide (anti‐PPS) determined using enzyme‐linked immunosorbent assay. The clinical follow‐up period lasted 6 months. The clinical outcomes were CMV disease and recurrent bacterial infections requiring antimicrobial therapy. Statistics: Multivariate logistic regression.Results: At day 7, IgG hypogammaglobulinemia (IgG levels < 700 mg/dL) combined with low IgG anti‐CMV antibody titers (defined as levels < 10 000 units) was present in 12% of kidney recipients. IgG hypogammaglobulinemia combined with low IgG anti‐PPS antibody titers (defined as levels < 10 mg/dL) at 1 month after kidney transplantation were recorded in 16% of patients. At day 7 the combination of IgG hypogammaglobulinemia and low anti‐CMV titers was independently associated with the development of CMV disease (odds ratio [OR], 6.95; 95% confidence interval [CI], 1.17‐41.31; P = .033). At day 30 after transplantation, the combination of IgG < 700 mg/dL and IgG anti‐PPS < 10 mg/dL, was independently associated with recurrent bacterial infection (OR, 5.942; 95% CI, 1.943‐18.172; P = .002).Conclusion: In a prospective multicenter study, early immunologic monitoring of secondary antibody deficiency proved useful for the identification of kidney recipients who developed severe infection.
- 1 August 2018
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 37 (8) , 1001-1012
Monitoring of early humoral immunity to identify lung recipients at risk for development of serious infections: A multicenter prospective study
- 1 August 2018
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 37 (8) , 1001-1012
Monitoring of early humoral immunity to identify lung recipients at risk for development of serious infections: A multicenter prospective study
- Open Access
- 1 May 2017
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 36 (5) , 529-539
Evaluation of humoral immunity profiles to identify heart recipients at risk for development of severe infections: A multicenter prospective study
- 1 May 2017
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 36 (5) , 529-539
Open AccessEvaluation of humoral immunity profiles to identify heart recipients at risk for development of severe infections: A multicenter prospective study
- 17 September 2016
- Published by Wiley in Transplant Infectious Disease
- Vol. 18 (6) , 832-843
Early intravenous immunoglobulin replacement in hypogammaglobulinemic heart transplant recipients: results of a clinical trial
Background: Immunoglobulin G (IgG) hypogammaglobulinemia (HGG) is a risk factor for development of severe infections after heart transplantation. We performed a clinical trial to preliminarily evaluate the efficacy and safety of early administration of intravenous immunoglobulin (IVIG) for prevention of severe infection in heart recipients with post‐transplant IgG HGG.Methods: Twelve heart recipients with IgG HGG detected in a screening phase of the clinical trial (IgG 750 mg/dL. IgG and specific antibody titers to distinct microorganisms were tested during follow‐up. The primary outcome measure was development of severe infection during the study period. Data on the primary outcome were matched with those of 13 recipients with post‐transplant HGG who were not included in the clinical trial and with those of 11 recipients who did not develop HGG during the same study period.Results: Mean time to detection of HGG was 15 days. IgG and specific antibody reconstitution (anti‐cytomegalovirus, anti‐Haemophilus influenza, and anti‐hepatitis B surface antigen antibodies) was observed in IVIG‐treated patients. Severe infection was detected in 3 of 12 (25%) IVIG‐treated recipients, in 10 of 13 (77%) HGG non‐IVIG patients, and in 2 of 11 (18%) non‐HGG patients (log‐rank, 15.31; P=.0005). No severe IVIG‐related side effects were recorded.Conclusion: Data from this study demonstrate that prophylactic IVIG replacement therapy safely modulates HGG and specific antimicrobial antibodies. Our data also preliminarily suggest that IVIG replacement therapy might decrease the incidence of severe infection in heart recipients with HGG.
- 17 September 2016
- Published by Wiley in Transplant Infectious Disease
- Vol. 18 (6) , 832-843
Early intravenous immunoglobulin replacement in hypogammaglobulinemic heart transplant recipients: results of a clinical trial
Background: Immunoglobulin G (IgG) hypogammaglobulinemia (HGG) is a risk factor for development of severe infections after heart transplantation. We performed a clinical trial to preliminarily evaluate the efficacy and safety of early administration of intravenous immunoglobulin (IVIG) for prevention of severe infection in heart recipients with post‐transplant IgG HGG.Methods: Twelve heart recipients with IgG HGG detected in a screening phase of the clinical trial (IgG 750 mg/dL. IgG and specific antibody titers to distinct microorganisms were tested during follow‐up. The primary outcome measure was development of severe infection during the study period. Data on the primary outcome were matched with those of 13 recipients with post‐transplant HGG who were not included in the clinical trial and with those of 11 recipients who did not develop HGG during the same study period.Results: Mean time to detection of HGG was 15 days. IgG and specific antibody reconstitution (anti‐cytomegalovirus, anti‐Haemophilus influenza, and anti‐hepatitis B surface antigen antibodies) was observed in IVIG‐treated patients. Severe infection was detected in 3 of 12 (25%) IVIG‐treated recipients, in 10 of 13 (77%) HGG non‐IVIG patients, and in 2 of 11 (18%) non‐HGG patients (log‐rank, 15.31; P=.0005). No severe IVIG‐related side effects were recorded.Conclusion: Data from this study demonstrate that prophylactic IVIG replacement therapy safely modulates HGG and specific antimicrobial antibodies. Our data also preliminarily suggest that IVIG replacement therapy might decrease the incidence of severe infection in heart recipients with HGG.
- 22 January 2015
- Published by Taylor & Francis in Infectious Diseases
- Vol. 47 (4) , 260-262
Potential role of serum BAFF as a biomarker in HIV infection
We evaluated the potential role of serum B-cell activating factor (BAFF) as a biomarker in HIV infection and analyzed the relationship between BAFF concentration and the immunophenotypic activation status of T-cells. We tested the hypothesis that higher serum BAFF concentrations are associated with risk for development of AIDS in HIV positive individuals. Forty-one HIV patients (CDC category A 17, category B 24) were evaluated retrospectively. Serum BAFF concentrations were assessed using a commercial enzyme-linked immunosorbent assay. Cox regression was used to estimate the probability for development of AIDS. Patients with higher BAFF concentrations (> 2100 pg/mL) were at greater risk of developing AIDS (relative hazard 5.69; p = 0.0033). BAFF levels were independently associated with risk of AIDS after adjustment by clinical risk factors. Serum BAFF was correlated with activated T-cell subsets and with neopterin levels. BAFF is a good candidate for further evaluation as a nonspecific surrogate marker in HIV infection.
- 22 January 2015
- Published by Taylor & Francis in Infectious Diseases
- Vol. 47 (4) , 260-262
Potential role of serum BAFF as a biomarker in HIV infection
We evaluated the potential role of serum B-cell activating factor (BAFF) as a biomarker in HIV infection and analyzed the relationship between BAFF concentration and the immunophenotypic activation status of T-cells. We tested the hypothesis that higher serum BAFF concentrations are associated with risk for development of AIDS in HIV positive individuals. Forty-one HIV patients (CDC category A 17, category B 24) were evaluated retrospectively. Serum BAFF concentrations were assessed using a commercial enzyme-linked immunosorbent assay. Cox regression was used to estimate the probability for development of AIDS. Patients with higher BAFF concentrations (> 2100 pg/mL) were at greater risk of developing AIDS (relative hazard 5.69; p = 0.0033). BAFF levels were independently associated with risk of AIDS after adjustment by clinical risk factors. Serum BAFF was correlated with activated T-cell subsets and with neopterin levels. BAFF is a good candidate for further evaluation as a nonspecific surrogate marker in HIV infection.